Business
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2
About this update from Pharvaris N.v.
ZUG, Switzerland , Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS ), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of two abstracts for oral presentation and six for poster presentation at the American College of Allergy , Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting to be held from November 6-10 , in Orlando, Florida . Details of the presentations are as follows: ACAAI 2025 , Orlando, Florida , November 6-10, 2025 . Oral Presentations Title: Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema Presenter: Evangelia Pardali, Ph.D. Format: Oral Presentation Date, time: Saturday, November 8 , 4:43 p.m. ET Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension Presenter: Marc A. Riedl , M.D., M.S. Format: Oral Presentation Date, time: Saturday, November 8 , 4:53 p.m. ET Poster Presentations Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1 Presenter: Michael E. Manning , M.D. Format: Poster Presentation Date, time: Friday, November 7 , 2:35 p.m. ET Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results Presenter: John Anderson , M.D. Format: Poster Presentation Date, time: Friday, November 7 , 2:35 p.m. ET Title: Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis Presenter: Mark D. Scarupa , M.D. Format: Poster Presentation Date, time: Friday, November 7 , 4:35 p.m. ET Title: Durability of Response to Single Dose Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks Presenter: Joshua S. Jacobs , M.D. Format: Poster Presentation Date, time: Friday, November 7 , 5:05 p.m. ET Title: Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results Presenter: John Anderson , M.D. Format: Poster Presentation Date, time: Friday, November 7 , 5:20 p.m. ET Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks Presenter: Zhi-Yi Zhang , Ph.D. Format: Poster Presentation Date, time: Friday, November 7 , 5:35 p.m. ET The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations . About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/ . Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications [email protected] Source: Pharvaris N.V.